The effect of the levonorgestrel-releasing intrauterine system, Mirena® on mast cell numbers in women with endometriosis undergoing symptomatic treatment

Samuel L Engemise, Samuel Engemise, Engemise SL, Willets JM, Jonathon M. Willets, Emembolu JO, J.O. Emembolu, Joseph O Emembolu, Konje JC, Justin C. Konje
European journal of obstetrics, gynecology, and reproductive biology · 2011 · vol. 159(2) , pp. 439–442 · doi:10.1016/j.ejogrb.2011.09.007 · PMID:22018831 · W2081097805
Non-randomised trial OA: closed CC0 ⤵ 7 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-07 ⓘ

This study investigated the impact of the levonorgestrel-releasing intrauterine system (Mirena®) on mast cell counts in women with endometriosis experiencing symptomatic relief.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

OBJECTIVES: Mirena® has been shown to improve symptoms in women with minimal to moderate endometriosis. The precise mechanisms for this have not been thoroughly investigated. We investigate here one possible mechanism-alteration in the number of mast cells in the endometriotic tissue. STUDY DESIGN: Tissues (endometrial, endometriotic and normal peritoneal biopsies) prospectively collected from twenty-eight women with laparoscopically confirmed minimal to moderate endometriosis before and 6 months after treatment with Mirena® were processed for immunohistochemistry for ER and PR expression followed by toluidine blue staining for mast cells. Photographs were obtained and the receptors and mast cells identified and quantified. RESULTS: The mean (± SEM) age of the twenty-eight women was 31 (±7.2) (range 18-42) years. Eight of the endometrial biopsies were in the proliferative phase and twenty in the secretory phase. Six months after Mirena®, the number of mast cell expressed in the tissues decreased significantly in the eutopic (P=0.0358) and ectopic endometrium (P=0.0220) but not in the normal peritoneum (P>0.05). There were no ERs or PRs found in mast cells. CONCLUSION: Mirena® causes a reduction in mast cell numbers in ectopic and eutopic endometrium in women undergoing symptomatic treatment of minimal to moderate endometriosis. This reduction could partly explain the efficacy of Mirena® in modulating pain in these women.

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Contraceptive Agents, Female Endometriosis Endometriosis Intrauterine Devices, Medicated Intrauterine Devices, Medicated Levonorgestrel Mast Cells Adolescent Adolescent Adult Adult Biopsy Biopsy Cell Count Cell Count Contraceptive Agents, Female Contraceptive Agents, Female Contraceptive Agents, Female Endometriosis Endometriosis

Citation neighborhood (2-hop)

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]

References (25)

Cited by (7)

Source provenance

europepmc
last seen: 2026-10-15T06:08:49.021275+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-10-08T21:09:35.770675+00:00
unpaywall
last seen: 2026-10-15T06:24:24.424788+00:00
License: CC0 · commercial use OK